Staff

Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA® (tocilizumab)Biosimilars...

BYTE Acquisition Corporation Announces Exercise and Closing of Over-Allotment Option in Initial Public Offering Resulting in Approximately $324 Million of Gross IPO Proceeds

NEW YORK--(BUSINESS WIRE)--BYTE Acquisition Corporation (the “Company”), a special purpose acquisition company, today announced that Citigroup Global Markets Inc. partially...

error: Content is protected !!